Secukinumab in multi-failure psoriatic patients: the last hope?
J Dermatolog Treat
; 29(6): 583-585, 2018 Sep.
Article
en En
| MEDLINE
| ID: mdl-29334270
ABSTRACT
Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form. Those patients can be treated with a systemic agent and in case of scarce response or contraindications, they may require a biologic therapy, such as tumor necrosis factor or interleukin-12/23 inhibitors. When also these agents fail, clinicians face a true therapeutic challenge. We report a case series of multi-failure 16 patients, successfully treated with secukinumab, a human monoclonal antibody that selectively neutralizes interleukin-17 A and is recently approved for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Fármacos Dermatológicos
/
Anticuerpos Monoclonales
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2018
Tipo del documento:
Article